NASDAQ:BCLI', 'Brainstorm Cell Therapeutics Inc.', '');

It Seems Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Will Go Down. Just Reported More Shorted Shares

December 8, 2017 - By Michael Collier

 It Seems Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Will Go Down. Just Reported More Shorted Shares

The stock of Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) registered an increase of 3.31% in short interest. BCLI’s total short interest was 1.01M shares in December as published by FINRA. Its up 3.31% from 977,600 shares, reported previously. With 83,600 shares average volume, it will take short sellers 12 days to cover their BCLI’s short positions. The short interest to Brainstorm Cell Therapeutics Incorporated’s float is 6.26%.

The stock decreased 0.50% or $0.02 during the last trading session, reaching $4.02. About 18,306 shares traded. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has risen 82.38% since December 8, 2016 and is uptrending. It has outperformed by 65.68% the S&P500.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company has market cap of $75.75 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. It currently has negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

More notable recent Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news were published by: which released: “BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company …” on September 27, 2017, also with their article: “BrainStorm Seeking Approval To Distribute NurOwn® in Canada” published on February 21, 2017, published: “BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q2 2017 Results …” on August 16, 2017. More interesting news about Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) were released by: and their article: “Brainstorm Cell Therapeutics (BCLI) Announces Presentation of New Data from …” published on December 14, 2016 as well as‘s news article titled: “BrainStorm Cell Therapeutics ALS Data Not As Promising As Press Releases Indicate” with publication date: April 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.